{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T04:11:45Z","timestamp":1775362305526,"version":"3.50.1"},"reference-count":230,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.critrevonc.2005.01.006","type":"journal-article","created":{"date-parts":[[2005,3,22]],"date-time":"2005-03-22T12:34:32Z","timestamp":1111494872000},"page":"45-65","source":"Crossref","is-referenced-by-count":20,"title":["New cytotoxic agents: a review of the literature"],"prefix":"10.1016","volume":"55","author":[{"given":"Katsuyuki","family":"Hotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ueoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2005.01.006_bib1","first-page":"9","article-title":"Origins and development of chemotherapy research at the National Cancer Institute","volume":"68","author":"Zubrod","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib2","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib3","first-page":"133","article-title":"A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies","volume":"23","author":"Nyman","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib4","first-page":"134","article-title":"Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers","volume":"23","author":"Syed","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib5","first-page":"704","article-title":"Phase 1 study of CT-2103 in patients with non-small cell lung cancer","volume":"22","author":"Shipley","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib6","first-page":"111a","article-title":"Phase I and pharmacological study of CT-2103, a poly (l-glutamic acid)\u2013paclitaxel conjugate","volume":"20","author":"Todd","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib7","first-page":"241","article-title":"A phase I and pharmacokinetic study of a novel oral taxane BAY 59-8862 in solid tumors","volume":"22","author":"Tonkin","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib8","first-page":"161","article-title":"A phase I and pharmacokinetic study of a novel taxane BAY 59-8862 with a weekly schedule","volume":"22","author":"Laurence","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib9","first-page":"100a","article-title":"A phase I and pharmacokinetic study of a novel taxane BAY59-8862","volume":"21","author":"Creaven","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/annonc\/mdf174","article-title":"Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR109881A administered as a 1h or a 3h infusion in patients with advanced solid tumors","volume":"13","author":"Sessa","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib11","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2000.18.24.4098","article-title":"Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors","volume":"18","author":"Gelmon","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib12","first-page":"194a","article-title":"A phase I and pharmacokinetics (PK) study of RPR 109881A given as 6h IV infusion in patients with advanced solid tumors","volume":"17","author":"Barthier","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib13","first-page":"194a","article-title":"Phase I trial of RPR 109881A (RPR), a novel taxoid derivative, administered as a 24h continuous infusion","volume":"17","author":"Slaughter","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib14","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2000.18.17.3164","article-title":"Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1h intravenous infusion in patients with advanced solid tumors","volume":"18","author":"Kurata","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib15","first-page":"146","article-title":"Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily\u00d77 every 3 weeks","volume":"23","author":"Kobayashi","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib16","first-page":"129","article-title":"Phase I study of 21-day continuous dosing of the oral antimitotic agent ABT-751","volume":"22","author":"Sprague","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib17","first-page":"147","article-title":"Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors","volume":"23","author":"Cho","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib18","first-page":"108a","article-title":"Phase I first in main study of the epothilone B analog BMS-247750 in patients with advanced cancer","volume":"20","author":"Spriggs","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib19","first-page":"94b","article-title":"Phase I clinical trial of BMS-247750 in adult patients with advanced solid tumors","volume":"20","author":"Lorusso","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib20","first-page":"108a","article-title":"Phase I clinical and pharmacology study of the epothilone B analog BMS-247750 given weekly in patients with advanced solid tumors","volume":"20","author":"Awada","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-0919-03","article-title":"Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors","volume":"10","author":"Mani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib22","first-page":"118","article-title":"A phase I\/II trial of BMS-247550 for patients with recurrent high-grade gliomas","volume":"23","author":"Peereboom","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib23","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1200\/JCO.2003.03.063","article-title":"Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days","volume":"21","author":"Abraham","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib24","first-page":"108a","article-title":"A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors","volume":"20","author":"Calvert","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib25","first-page":"473","article-title":"A phase I\/II dose-escalation trial of EPO906 every 3 weeks in patients with relapsed\/refractory ovarian, primary fallopian, or primary peritoneal cancer","volume":"23","author":"Smit","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib26","first-page":"675","article-title":"A phase I\/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC)","volume":"23","author":"Oesterlind","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib27","first-page":"68a","article-title":"A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies","volume":"20","author":"Rubin","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib28","first-page":"135","article-title":"KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies","volume":"22","author":"Piro","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2005.01.006_bib29","first-page":"6129s","article-title":"Phase 1 dose escalating and pharmacokinetic (PK) study of KOS-862 (epothilone D): phase 2 dose and schedule defined","volume":"9","author":"Spriggs","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib30","first-page":"133","article-title":"Phase I study using continuous intravenous (CI) KOS-862 (epothilone D) in patients with solid tumors","volume":"23","author":"Holen","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib31","first-page":"104a","article-title":"KOS-862 (epothilone D): results of a phase I dose-escalating trial in patients with advanced malignancies","volume":"21","author":"Rosen","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib32","series-title":"Proceedings of the AACR-NCI-EORTC International Conference, vol. 113","article-title":"A phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer (NSCLC)","author":"Horti","year":"2003"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib33","series-title":"Proceedings of the AACR-NCI-EORTC International Conference, vol. 112","article-title":"Phase I and pharmacologic study of TZT-1027, a novel dolastatin 10 derivative, administered in a day 1 and 8 iv schedule every 3 weeks in patients (pts) with advanced solid tumors","author":"Verweij","year":"2003"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdh141","article-title":"Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1h intravenous infusion every 3 weeks in patients with advanced refractory cancer","volume":"15","author":"Schoffski","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib35","first-page":"29","article-title":"A phase I study of ILX-651 administered intravenously daily for five days every three weeks in patients with advanced solid tumors","volume":"22","author":"Ebbinghaus","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib36","first-page":"205","article-title":"ILX651, a third generation dolastatin 15: results of a phase I dose escalating and pharmacokinetic study of ILX-651 administered as a 30 minute IV infusion every other day for 3 days every three weeks","volume":"22","author":"Eder","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib37","first-page":"213","article-title":"Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly\u00d73 weeks every 4 weeks (w\u00d73q4w)","volume":"23","author":"Weiss","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib38","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1200\/JCO.2000.18.23.3986","article-title":"Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30min infusion every 3 weeks in patients with advanced cancer","volume":"18","author":"Boige","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib39","first-page":"3056","article-title":"Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30min every three weeks","volume":"7","author":"Minami","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib40","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.2000.18.17.3151","article-title":"DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies","volume":"18","author":"Rowinsky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib41","series-title":"Proceedings of the AACR-NCI-EORTC International Conference","article-title":"Phase I and pharmacokinetic (PK) study of DX-8951f, a novel camptothecin analog, given as 30min infusion daily for 5 days","author":"Kamiya","year":"1999"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib42","first-page":"2134","article-title":"Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia","volume":"8","author":"Giles","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib43","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1200\/JCO.2001.19.5.1493","article-title":"Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog","volume":"19","author":"Royce","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib44","first-page":"3963","article-title":"Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24h infusions three of every four weeks","volume":"7","author":"Sharma","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/annonc\/mdg243","article-title":"Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30min intravenous infusion, in patients with advanced solid malignancies","volume":"14","author":"Braybrooke","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib46","first-page":"2527","article-title":"A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies","volume":"9","author":"Garrison","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib47","first-page":"195a","article-title":"Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advanced solid tumors using accelerated dose titration","volume":"19","author":"Schilsky","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00001813-199801000-00004","article-title":"A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor","volume":"9","author":"Verschraegen","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib49","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-03-0288","article-title":"Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors","volume":"10","author":"Zamboni","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","article-title":"Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers","volume":"21","author":"Kantarjian","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib51","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib52","first-page":"223","article-title":"Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study","volume":"23","author":"Cunningham","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib53","first-page":"605","article-title":"A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate","volume":"4","author":"McDonald","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib54","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1200\/JCO.1995.13.11.2842","article-title":"Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation","volume":"13","author":"Rinaldi","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib55","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","article-title":"Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours","volume":"11","author":"Schoffski","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/PL00008463","article-title":"Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours","volume":"126","author":"Schoffski","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib58","first-page":"590","article-title":"High efficacy and better hematological safety of reduced dose of bendamustine in extendedly pretreated patients with advanced, relapsed or refractory B-CLL: phase I\/II study of the German CLL study group","volume":"22","author":"Bergmann","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib59","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/jnci\/85.22.1812","article-title":"Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee","volume":"85","author":"Philip","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/bjc.1995.356","article-title":"A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24h intravenous infusion","volume":"72","author":"Jayson","year":"1995","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib61","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/bjc.1993.352","article-title":"A phase I study of intravenous bryostatin 1 in patients with advanced cancer","volume":"68","author":"Prendiville","year":"1993","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.1998.16.1.56","article-title":"Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"16","author":"Varterasian","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4161\/cbt.1.4.17","article-title":"Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies","volume":"1","author":"Marshall","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib64","first-page":"97a","article-title":"Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days","volume":"21","author":"Yamada","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib65","first-page":"177a","article-title":"A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule","volume":"19","author":"Lewis","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib66","first-page":"797a","article-title":"Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days","volume":"19","author":"Peck","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00001813-200401000-00003","article-title":"Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)","volume":"15","author":"Mross","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib68","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2000.18.24.4086","article-title":"Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies","volume":"18","author":"Eckhardt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1006432012394","article-title":"Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia","volume":"19","author":"Giles","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s002800100365","article-title":"Phase I clinical and pharmacokinetic trial of irofulven","volume":"48","author":"Thomas","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib71","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-03-0349","article-title":"Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients","volume":"10","author":"Alexandre","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib72","first-page":"84b","article-title":"Phase I study of irofulven (MGI 114) given weekly (D1\u2013D8) as a 5 infusion every 3 weeks (W): preliminary results","volume":"20","author":"Raymond","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib73","first-page":"92b","article-title":"Phase I study of irofulven (MGI 114) given weekly as a 5 infusion on days 1, 8, 15 every 4 weeks (W): preliminary results","volume":"20","author":"Kahatt","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib74","first-page":"1628","article-title":"Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies","volume":"9","author":"Rosen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib75","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1158\/1078-0432.CCR-03-0687","article-title":"Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies","volume":"10","author":"Rosen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib76","first-page":"146","article-title":"Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days","volume":"23","author":"Chu","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib77","first-page":"128","article-title":"Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days","volume":"23","author":"Burris","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib78","first-page":"17","article-title":"ABI-007 nanoparticle paclitaxel: demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer","volume":"22","author":"Blum","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib79","first-page":"53a","article-title":"Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in two multicenter phase II studies","volume":"21","author":"Ibrahim","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib80","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2004.12.043","article-title":"Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"22","author":"Sabbatini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib81","first-page":"42","article-title":"A phase 2 study of CT-2103, a poly(l-glutamic acid)\u2013paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer","volume":"22","author":"Robson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib82","first-page":"653","article-title":"Phase 2 study of first line chemotherapy using CT-2103 in patients with non-small-cell lung cancer who are >70 years of age or performance status (PS)=2","volume":"22","author":"Norton","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib83","first-page":"283","article-title":"Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen","volume":"22","author":"Schulz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib84","first-page":"647","article-title":"An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer","volume":"23","author":"Gurtler","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib85","first-page":"44","article-title":"A phase II trial of a novel taxane BAY 59-8862 in patients with advanced taxane-resistant breast cancer","volume":"22","author":"Amadori","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib86","first-page":"408","article-title":"An uncontrolled phase II multi-center trial evaluating anti-tumor efficacy and safety of BAY 59-8862 in patients with advanced renal cell cancer","volume":"22","author":"Cobb","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib87","first-page":"141","article-title":"A multicentre, non-randomized phase II study with RPR 109881A in metastatic breast cancer (MBC) patients (pts)","volume":"22","author":"Dieras","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib88","first-page":"8","article-title":"A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC)","volume":"22","author":"Thomas","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib89","first-page":"18","article-title":"A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline","volume":"22","author":"Roche","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib90","first-page":"13","article-title":"A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily\u00d75 in breast cancer","volume":"23","author":"Low","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib91","first-page":"281","article-title":"Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer","volume":"22","author":"Singh","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib92","first-page":"155a","article-title":"Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane","volume":"21","author":"Ajani","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib93","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdh236","article-title":"A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer","volume":"15","author":"Eng","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib94","first-page":"383","article-title":"Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A southwest oncology group study (S0111)","volume":"23","author":"Hussain","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib95","first-page":"155","article-title":"Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers","volume":"23","author":"Chen","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib96","first-page":"315","article-title":"A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a southwest oncology group study","volume":"23","author":"Whitehead","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib97","first-page":"717","article-title":"A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM)","volume":"23","author":"Pavlick","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib98","first-page":"393","article-title":"A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer","volume":"23","author":"Zhuang","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib99","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib100","first-page":"396","article-title":"A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC)","volume":"23","author":"Hussain","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib101","first-page":"283","article-title":"Safety and efficacy of EPO906 in patients with advanced colorectal cancer: a review of 2 phase II trials","volume":"22","author":"Poplin","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib102","first-page":"405","article-title":"Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer","volume":"22","author":"Thompson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib103","first-page":"714","article-title":"Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qd\u00d75q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma","volume":"23","author":"Ebbinghaus","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib104","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.11557","article-title":"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma","volume":"98","author":"Esteva","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/B:DRUG.0000006174.87869.6b","article-title":"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum","volume":"22","author":"Royce","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib106","first-page":"1","article-title":"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan","volume":"53","author":"Verschraegen","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib107","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ygyno.2004.06.047","article-title":"A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant\/refractory ovarian cancer","volume":"95","author":"Clamp","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0169-5002(03)00190-9","article-title":"Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced or metastatic non-small cell lung cancer","volume":"41","author":"Braybrooke","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib109","series-title":"Proceedings of the Gastrointestinal Cancers Symposium","article-title":"A phase II study of intravenous DX-8951f administered daily for five days, every three weeks to patients with biliary tree cancer (cholangiocarcinoma and gallbladder cancer)","author":"Abou-Alfa","year":"2004"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib110","series-title":"Proceedings of the Gastrointestinal Cancers Symposium","article-title":"A phase II study of intravenous DX-8951f administered daily for five days, every three weeks to patients with hepatocellular carcinoma","author":"Patt","year":"2004"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib111","first-page":"343","article-title":"A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer","volume":"23","author":"Becerra","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib112","series-title":"Proceedings of the Gastrointestinal Cancers Symposium","article-title":"DX-8951f in advanced pancreatic cancer (APC)","author":"Reilly","year":"2004"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib113","first-page":"673","article-title":"Phase II trial of karenitecin in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004","volume":"22","author":"Herndon","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib114","first-page":"720","article-title":"Phase II trial of karenitecin (BNP1350) in malignant: clinical and translational study","volume":"23","author":"Hausheer","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib115","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0959-8049(02)00070-9","article-title":"Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme","volume":"38","author":"Raymond","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib116","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001813-200202000-00009","article-title":"Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma","volume":"13","author":"Ellerhorst","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0959-8049(02)00022-9","article-title":"Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue","volume":"38","author":"Schoffski","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib118","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/cncr.11385","article-title":"Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas","volume":"97","author":"Patel","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib119","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ejca.2004.02.016","article-title":"RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC new drug development group","volume":"40","author":"Punt","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/B:DRUG.0000006176.84915.71","article-title":"A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer","volume":"22","author":"Miller","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib121","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.urolonc.2004.05.002","article-title":"9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: results of the CALGB 99901","volume":"22","author":"Amin","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib122","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/B:DRUG.0000026260.24275.02","article-title":"Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors","volume":"22","author":"de Jonge","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib123","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001813-199904000-00005","article-title":"A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer","volume":"10","author":"Verschraegen","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib124","first-page":"262a","article-title":"A phase II study of rubitecan (RFS2000, 9NC, 9-nitro-20(S)-camptothecin) in patients with refractory pancreatic cancer","volume":"19","author":"Rivkin","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib125","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800100360","article-title":"A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma","volume":"48","author":"Konstadoulakis","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib126","first-page":"821","article-title":"A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer","volume":"14","author":"Stehlin","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib127","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib128","first-page":"796","article-title":"Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias","volume":"23","author":"Jeha","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib129","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non-small cell lung cancer: phase II study","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy naive patients with advanced non-small cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib131","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/annonc\/mdg099","article-title":"ALIMTA as second-line treatment of non-small cell lung cancer: a phase II study","volume":"14","author":"Smit","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib132","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1023\/A:1008372529239","article-title":"Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC clinical trials group study","volume":"10","author":"Cripps","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib133","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and Vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib134","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1008305205159","article-title":"Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer","volume":"11","author":"Miller","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/annonc\/mdf189","article-title":"Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"13","author":"Weidmann","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib136","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","article-title":"Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia","volume":"127","author":"Kath","year":"2001","journal-title":"Cancer Res Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib138","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s004320050225","article-title":"Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study","volume":"124","author":"Hoffken","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib139","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00001813-200008000-00003","article-title":"Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib140","first-page":"599","article-title":"Bendamustine weekly: an effective and well tolerated regimen for indolent NHL (non-Hodgkin's lymphoma) and B-CLL (chronic lymphocytic leukemia)","volume":"22","author":"Bremer","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib141","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1014449309165","article-title":"A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"20","author":"Pfister","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib142","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1010628903248","article-title":"Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer","volume":"19","author":"Brockstein","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib143","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1010676719178","article-title":"Phase II study of bryostatin 1 in patients with relapsed multiple myeloma","volume":"19","author":"Varterasian","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib144","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1054\/bjoc.2000.1624","article-title":"A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma","volume":"84","author":"Blackhall","year":"2001","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib145","first-page":"38","article-title":"A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer","volume":"7","author":"Zonder","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib146","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/sj.bjc.6601285","article-title":"A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma","volume":"89","author":"Clamp","year":"2003","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib147","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/bjc.1998.680","article-title":"A phase II study of bryostatin 1 in metastatic malignant melanoma","volume":"78","author":"Propper","year":"1998","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib148","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00008390-199912000-00010","article-title":"Treatment of patients with metastatic melanoma with bryostatin-1\u2014a phase II study","volume":"9","author":"Gonzalez","year":"1999","journal-title":"Melanoma Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib149","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008390-200104000-00014","article-title":"Phase II evaluation of bryostatin-1 in metastatic melanoma","volume":"11","author":"Bedikian","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib150","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/sj.bjc.6601321","article-title":"A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer","volume":"89","author":"Madhusudan","year":"2003","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib151","first-page":"109","article-title":"Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study","volume":"9","author":"Haas","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib152","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/1097-0142(20000801)89:3<615::AID-CNCR17>3.0.CO;2-J","article-title":"A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma","volume":"89","author":"Pagliaro","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib153","first-page":"825","article-title":"Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"6","author":"Varterasian","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib154","first-page":"159a","article-title":"Phase II trials of J-107088, a novel topoisomerase I inhibitor, in irinotecan naive\/refractory metastatic colorectal cancer","volume":"21","author":"Perez","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib155","first-page":"274","article-title":"Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naive metastatic colorectal cancer","volume":"22","author":"Nahum","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib156","first-page":"416","article-title":"Phase II study on the activity and tolerability of BBR 3576 given to patients with advanced hormone refractory prostrate cancer (HRPC)","volume":"22","author":"Droz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib157","first-page":"276","article-title":"Phase II trial of irofulven in patients with unrespectable hepatocellular carcinoma (HCC)","volume":"22","author":"Stuart","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib158","first-page":"333","article-title":"Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unrespectable hepatocellular carcinoma (HCC): preliminary results","volume":"23","author":"Falcon-Lizaraso","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib159","first-page":"218a","article-title":"Phase II study of irofulven in platinum resistant recurrent ovarian cancer","volume":"20","author":"Sarosy","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib160","first-page":"399a","article-title":"Phase II study of irofulven (MGI-114) in platinum (P) and paclitaxel (T) resistant epithelial ovarian cancer (OC)","volume":"19","author":"Vukelja","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib161","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/B:DRUG.0000026262.77502.31","article-title":"Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the gynecologic oncology group","volume":"22","author":"Schilder","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib162","first-page":"357a","article-title":"A phase II trial of irofulven (MGI 114) in patients with hormone-refractory prostate cancer","volume":"19","author":"Senzer","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib163","first-page":"446","article-title":"Clinical activity of irofulven in hormone refractory prostate cancer","volume":"23","author":"Cvitkovic","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib164","first-page":"309a","article-title":"Phase II trial of irofulven (MGI 114) in patients with advanced pancreatic cancer who have progressed on gemcitabine","volume":"19","author":"Von Hoff","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/A:1016261918256","article-title":"A phase II study of irofulven (MGI 114) in patients with stage IV melanoma","volume":"20","author":"Pierson","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib166","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00000421-200304000-00006","article-title":"Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer","volume":"26","author":"Nasta","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib167","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1010609810517","article-title":"Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma","volume":"19","author":"Berg","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1006433528750","article-title":"A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy","volume":"19","author":"Dowell","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib169","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2004.02.017","article-title":"A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer","volume":"45","author":"Sherman","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib170","first-page":"16","article-title":"Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) as third-line therapy in patients with advanced metastatic breast cancer (MBC)","volume":"22","author":"Washington","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib171","first-page":"452","article-title":"Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory or resistant third-line advanced ovarian cancer","volume":"22","author":"Kavanagh","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib172","first-page":"655","article-title":"Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens","volume":"22","author":"Papadimitrakopoulou","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib173","first-page":"1051","article-title":"Potential neurotoxicity of the solvent vehicle for cyclosporine","volume":"268","author":"Windebank","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib174","article-title":"Evidence of enhanced in vivo efficacy at maximum tolerated dose (MTD) of nanoparticle paclitaxel (ABI-007) and taxol in 5 human tumor xenografts of varying sensitivity to paclitaxel","volume":"21","author":"Desai","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib175","series-title":"Proceedings of the 26th Annual San Antonio Breast Cancer Symposium","article-title":"ABI-007 (ABRAXANE\u2122), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy versus taxol in MBC: a phase III trial","author":"O'Shaughnessy","year":"2003"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib176","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1349-7006.2003.tb01465.x","article-title":"DJ-927, a novel orally active taxane, overcomes Pp-glycoprotein-mediated multidrug resistance in vitro and in vivo","volume":"94","author":"Shionoya","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib177","first-page":"2404","article-title":"Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)\u2013paclitaxel conjugate","volume":"58","author":"Li","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib178","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1248\/bpb.27.345","article-title":"Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys","volume":"27","author":"Ono","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib179","first-page":"161","article-title":"Phase 1 study of CT-2103\/carboplatin in patients with solid tumors","volume":"22","author":"Bolton","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib180","first-page":"2","article-title":"Single agent (SA) versus combination chemotherapy (CC) in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness","volume":"21","author":"Lilenbaum","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib181","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1039\/P19920002925","article-title":"14\u03b2-Hydroxy-10-deacetyl-baccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.)","volume":"1","author":"Appendino","year":"1992","journal-title":"J Chem Soc, Perkin Trans"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib182","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<844::AID-IJC22>3.0.CO;2-7","article-title":"Anti-proliferative activity of a new class of taxanes (14\u03b2-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells","volume":"72","author":"Distefano","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib183","first-page":"842","article-title":"IDN5109, a taxane with oral bioavailability and potent antitumor activity","volume":"60","author":"Nicoletti","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib184","first-page":"2647","article-title":"Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer","volume":"8","author":"Cassinelli","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib185","first-page":"2325","article-title":"Epothilones, a new class of microtubule stabilizing agents with a taxol-like mechanisms of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib186","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1074\/jbc.272.4.2534","article-title":"Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (taxol)","volume":"272","author":"Kowalski","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib187","first-page":"626","article-title":"A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy","volume":"22","author":"Vansteenkiste","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib188","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/annonc\/mdg415","article-title":"Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration","volume":"14","author":"Smaletz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib189","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.clon.2004.04.003","article-title":"Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): updated results","volume":"23","author":"Kelly","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib190","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1074\/jbc.272.4.2534","article-title":"Activities of the microtubule-stabilizing agents epothilone A and B with purified tubulin and in cells resistant to paclitaxel (taxol)","volume":"272","author":"Kowalski","year":"1997","journal-title":"J Biol Chem"},{"issue":"3 Suppl 6","key":"10.1016\/j.critrevonc.2005.01.006_bib191","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0093-7754(03)00125-8","article-title":"EPO906 (epothilone B): a promising novel microtubule stabilizer","volume":"30","author":"Rothermel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib192","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1073\/pnas.131153098","article-title":"The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice","volume":"98","author":"Chou","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib193","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1349-7006.1997.tb00383.x","article-title":"Antitumor activity of TZT-1027, a novel dolastatin 10 derivative","volume":"88","author":"Kobayashi","year":"1997","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib194","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1349-7006.2003.tb01526.x","article-title":"Antitumor activity of TZT-1027 (soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo","volume":"94","author":"Natsume","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib195","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1349-7006.1995.tb02468.x","article-title":"A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo","volume":"86","author":"Mitsui","year":"1995","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib196","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/13543784.7.4.625","article-title":"Antitumor activity of DX-8951f: a new camptothecin derivative","volume":"7","author":"Kumazawa","year":"1998","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib197","first-page":"99a","article-title":"A phase 1 study of DX-8951f (exatecan mesylate, DX) and gemcitabine (GEM) in advanced solid tumors","volume":"21","author":"O\u2019Reilly","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib198","first-page":"314","article-title":"A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) versus gemcitabine alone in advanced pancreatic cancer (APC)","volume":"23","author":"Reilly","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib199","first-page":"314","article-title":"Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC)","volume":"23","author":"Cheverton","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib200","first-page":"641","article-title":"Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins","volume":"8","author":"Garcia-Carbonero","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib201","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijc.10434","article-title":"Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance","volume":"100","author":"Van Hattum","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib202","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/S0021-9258(17)41964-8","article-title":"Structure\u2013activity study of the actions of camptothecin derivatives on mammalian topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin","volume":"269","author":"Jaxel","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib203","first-page":"461","article-title":"Preliminary pharmacologic and clinical evaluation of camptothecin sodium","volume":"54","author":"Gottleib","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib204","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032-triphosphate","volume":"51","author":"Parker","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib205","series-title":"Cancer Chemotherapy and Biologic Response Modifiers, Annal 19","first-page":"21","article-title":"Purine and pyrimidine nucleoside analogs","author":"Plunkett","year":"2001"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib206","first-page":"1116","article-title":"LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib207","first-page":"370","article-title":"Cell cycle modulation by the multi-targeted anti-folate, LY231514, increases the antiproliferative activity of gemcitabine","volume":"37","author":"Tonkinson","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib208","first-page":"76a","article-title":"Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA) a novel antifolate\/antimetabolite","volume":"20","author":"Bunn","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib209","first-page":"314","article-title":"A randomized phase III study comparing gemcitabine+pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer","volume":"23","author":"Richards","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib210","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib211","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib212","first-page":"619","article-title":"A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC lung cancer group and NCIC","volume":"23","author":"Van Meerbeeck","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib213","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib214","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00003495-200161050-00009","article-title":"Bendamustine","volume":"61","author":"Balfour","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib215","first-page":"592","article-title":"Bendamustine plus rituximab is highly effective in the treatment of advanced low-grade and mantle cell lymphomas with unfavorable prognosis","volume":"22","author":"Kim","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib216","first-page":"282a","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a new effective treatment for refractory or relapsed indolent lymphomas","volume":"21","author":"Koppler","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib217","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-2001-11316","article-title":"Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma","volume":"126","author":"Kath","year":"2001","journal-title":"Dtsch Med WochenschrS"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib218","first-page":"9a","article-title":"Multicentric prospective randomized trial of bendamustine\/prednisone versus melphalane\/prednisone in 136 patients with multiple myeloma","volume":"19","author":"Ponisch","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib219","first-page":"120a","article-title":"Bendamustin, MTX, 5-FU (BMF) versus cyclophosphamide, MTX, 5-FU (CMF) as first line therapy of metastatic breast cancer. A safety interim analysis","volume":"19","author":"Von Minckwitz","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib220","doi-asserted-by":"crossref","first-page":"21896","DOI":"10.1016\/S0021-9258(20)88269-6","article-title":"Interleukin-3 and bryostatin 1 mediate rapid nuclear envelope protein phosphorylation in growth factor-dependent FDC-P1 hematopoietic cells. A possible role for nuclear protein kinase C","volume":"264","author":"Fields","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib221","first-page":"682","article-title":"Successful treatment of murine melanoma with bryostatin 1","volume":"51","author":"Schuchter","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib222","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1026255403046","article-title":"A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"21","author":"Armstrong","year":"2003","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib223","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1025490818450","article-title":"A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Armstrong","year":"2003","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib224","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1023\/A:1020694425356","article-title":"A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: a National Cancer Institute of Canada clinical trials group study","volume":"20","author":"Tozer","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib225","first-page":"264","article-title":"Phase II study of bryostatin-1 (NSC 339555) plus paclitaxel in patients with metastatic or unrespectable locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"22","author":"Chang","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib226","first-page":"4271","article-title":"Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I","volume":"59","author":"Yoshinari","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0006-2952(99)00085-4","article-title":"Drug uptake and cellular targets of hydroxy methylacylfulvene (HMAF)","volume":"58","author":"Herzig","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib228","first-page":"279","article-title":"Preclinical antitumor activity of 6-hydroxymethlacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S","volume":"57","author":"McDonald","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib229","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/jm950005k","article-title":"Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase","volume":"39","author":"Satyam","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.critrevonc.2005.01.006_bib230","first-page":"2568","article-title":"Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase","volume":"58","author":"Morgan","year":"1998","journal-title":"Cancer Res"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842805000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842805000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T02:45:41Z","timestamp":1625625941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842805000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":230,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S1040842805000326"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2005.01.006","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}